Literature DB >> 1979581

Cell surface modulation of CD26 by anti-1F7 monoclonal antibody. Analysis of surface expression and human T cell activation.

N H Dang1, Y Torimoto, K Sugita, J F Daley, P Schow, C Prado, S F Schlossman, C Morimoto.   

Abstract

In this paper, we examined in detail the ability of anti-1F7 to modulate 1F7 (CD26) surface expression as well as analyzed the functional relationship between the surface expression of CD3, CD2, and CD26 and human T cell activation. We showed that anti-1F7-induced modulation is an energy-dependent process that occurs via capping and internalization of the Ag-antibody complex. Although the recovery rate for Ag reexpression of 1F7 following optimal modulation is relatively delayed, reexpression of 1F7 is greatly accelerated following phorbol ester treatment. Most importantly, we demonstrated that modulation of the CD26 Ag leads to an enhancement in the proliferative activity of modulated human T cells treated with anti-CD3 or anti-CD2, which is preceded by an enhancement in Ca2+ mobilization. CD26 modulation also led to an increase in anti-CD3- or anti-CD2-mediated T cell clone proliferation. Finally, whereas modulation of the CD26 Ag has an effect on CD3- or CD2-induced T cell activation, modulation of the CD3/TCR complex inhibits the proliferative response of T cells incubated with anti-CD3 plus anti-1F7 or anti-CD2 plus anti-1F7. However, modulation of the CD2 structure does not affect anti-CD3- plus anti-1F7-induced human T cell activation. The above results thus provide additional evidence that the CD26 Ag plays an integral role in the regulation of human T cell activation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1979581

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  34 in total

1.  CD26-mediated signaling for T cell activation occurs in lipid rafts through its association with CD45RO.

Authors:  T Ishii; K Ohnuma; A Murakami; N Takasawa; S Kobayashi; N H Dang; S F Schlossman; C Morimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-02       Impact factor: 11.205

2.  Cross-linking of CD26 by antibody induces tyrosine phosphorylation and activation of mitogen-activated protein kinase.

Authors:  M Hegen; J Kameoka; R P Dong; S F Schlossman; C Morimoto
Journal:  Immunology       Date:  1997-02       Impact factor: 7.397

3.  CD26 inhibition enhances allogeneic donor-cell homing and engraftment after in utero hematopoietic-cell transplantation.

Authors:  William H Peranteau; Masayuki Endo; Obinna O Adibe; Aziz Merchant; Philip W Zoltick; Alan W Flake
Journal:  Blood       Date:  2006-09-05       Impact factor: 22.113

4.  Inhibitors of dipeptidyl peptidase IV induce secretion of transforming growth factor-beta 1 in PWM-stimulated PBMC and T cells.

Authors:  D Reinhold; U Bank; F Bühling; U Lendeckel; J Faust; K Neubert; S Ansorge
Journal:  Immunology       Date:  1997-07       Impact factor: 7.397

5.  CD26 mediates dissociation of Tollip and IRAK-1 from caveolin-1 and induces upregulation of CD86 on antigen-presenting cells.

Authors:  Kei Ohnuma; Tadanori Yamochi; Masahiko Uchiyama; Kunika Nishibashi; Satoshi Iwata; Osamu Hosono; Hiroshi Kawasaki; Hirotoshi Tanaka; Nam H Dang; Chikao Morimoto
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

6.  Inhibition of dipeptidyl peptidase IV by fluoroolefin-containing N-peptidyl-O-hydroxylamine peptidomimetics.

Authors:  J Lin; P J Toscano; J T Welch
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

7.  The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity.

Authors:  T Tanaka; J Kameoka; A Yaron; S F Schlossman; C Morimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

8.  CD26 induces T-cell proliferation by tyrosine protein phosphorylation.

Authors:  E Muñoz; M V Blazquez; J A Madueño; G Rubio; J Peña
Journal:  Immunology       Date:  1992-09       Impact factor: 7.397

9.  Soluble CD26 is inversely Associated with Disease Severity in Patients with Chronic Eosinophilic Pneumonia.

Authors:  Osamu Matsuno; Eishi Miyazaki; Shinichi Nureki; Takuya Ueno; Masaru Ando; Toshihide Kumamoto
Journal:  Biomark Insights       Date:  2007-02-07

10.  Effect of CD26/dipeptidyl peptidase IV on Jurkat sensitivity to G2/M arrest induced by topoisomerase II inhibitors.

Authors:  U Aytac; K Sato; T Yamochi; T Yamochi; K Ohnuma; G B Mills; C Morimoto; N H Dang
Journal:  Br J Cancer       Date:  2003-02-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.